Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The object of the study is to investigate whether all included patients receive treatment that is effective against all bacteria that are defined as sensitive to meropenem with the current treatment regimen. Will the investigators findings motivate routine monitoring of plasma concentrations in children receiving meropenem? Up to 50 patients will be included in the study, and all participants are children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy

NCT01109589

Respiratory Tract Diagnoses (ICPC-2) Prescriptions of Antibiotics by General Practitioners Prescriptions of ATC J01 and R Drugs in Participants

COMPLETED

Assess a Diagnostic Tool to Distinguish Between Bacterial and Viral Infection

NCT01931254

Lower Respiratory Tract Infection Unspecified Fever

COMPLETED

Antibiotic Therapy in Viral Airway Infections

NCT05045612

Infectious Disease Influenza Respiratory Syncytial Virus (RSV) +1 more

RECRUITING PHASE4

Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19

NCT04381819

SARS Virus Severe Acute Respiratory Syndrome

UNKNOWN

The Corona Study of Middle Norway

NCT05638178

SARS-CoV-2 Acute Respiratory Disease SARS-CoV-2 Sepsis SARS CoV 2 Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children receiving meropenem

Children aged from 3 months to 18 years that receive treatment with meropenem.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged from 3 months to 18 years that receive treatment with meropenem. Inclusion is independent of how long the patient has been receiving treatment. Children receiving other treatment (except hemodialysis)/other medications can be included.